ANRF News
The 2026 ANRF Impact Report Is Here
Decades of discovery. A model that works. And the science that comes next. Arthritis and autoimmune disease research doesn’t announce itself. It builds — through
June 30, 2026
Awareness Month Tribute
This month only, make a gift in honor of someone who has shown up for you — and they'll receive a personal thank you message from ANRF Board member and RA survivor Staci Stringer Betschart.
It's a meaningful way to celebrate the people in your village while fueling the research that's changing lives.
Make Your GiftDon't wait — this opportunity is available this month only.
Decades of discovery. A model that works. And the science that comes next. Arthritis and autoimmune disease research doesn’t announce itself. It builds — through
As demand for independent research funding reaches an all-time high, the Arthritis National Research Foundation answers with its largest cohort, its biggest financial commitment, and
Veteran biotech investor to steer IBC’s impact fund targeting early-stage therapies, diagnostics, and technologies for immune disorders. Immune Boost Capital (IBC), the newly formed venture
This year, more scientists applied for arthritis and autoimmune disease research funding than at any point in the Arthritis National Research Foundation’s 50-year history. It
Industry Veteran to Lead New Philanthropic Venture Fund Addressing Critical Early-Stage Funding Gap in Autoimmune Therapeutics and Diagnostics The Arthritis National Research Foundation (ANRF), a
Each year, the Arthritis National Research Foundation (ANRF) looks forward to joining the global rheumatology community at ACR Convergence, the American College of Rheumatology’s annual
Make a one-time or recurring donation and know you are making a difference by funding cutting-edge arthritis & related autoimmune disease research.
Decades of discovery. A model that works. And the science that comes next. Arthritis and autoimmune disease research doesn’t announce itself. It builds — through
As demand for independent research funding reaches an all-time high, the Arthritis National Research Foundation answers with its largest cohort, its biggest financial commitment, and
Veteran biotech investor to steer IBC’s impact fund targeting early-stage therapies, diagnostics, and technologies for immune disorders. Immune Boost Capital (IBC), the newly formed venture